Sanofi spinoff EuroAPI’s shares plunge on sales surprise Sanofi still owns 30% of EuroAPI and the French state has a 12% stake, reflecting government efforts to bolster national… 2 years ago
Sanofi clinches vaccine deal with J&J to battle E. coli The partners agreed to a profit-share arrangement in the US, the UK and four European Union countries. 2 years ago
Lack of awareness, stigma continue to hamper life of Atopic Dermatitis patients in India Dr. Godse also highlighted that since the lesions are visible, there is a social stigma that affects the daily life… 2 years ago
Sanofi India gets marketing authorization for drug to treat atopic dermatitis Atopic dermatitis, a form of eczema, is a chronic type 2 inflammatory disease with symptoms often appearing as a rash… 2 years ago
French drugmaker Sanofi to demerge its consumer business in India Sanofi Consumer Healthcare India Limited is expected to be fully operational by the second half of 2024, subject to necessary… 3 years ago
Sanofi receives marketing approval for its diabetes drug in India Soliqua is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity… 3 years ago
Sanofi witnesses faster profit growth on Dupixent, flu vaccine Reportedly, revenue from exzema and asthma drug Dupixent, jointly developed with Regeneron, jumped by a currency-adjusted 44.5% to 2.3 billion… 3 years ago
Sanofi’s breast cancer treatment amcenestrant failed second trial; French firm halts further work A trial dubbed AMEERA-5, which was testing amcenestrant on women with newly diagnosed advanced breast cancer, was stopped early because… 3 years ago
After Zantac litigation dip, shares of drugmakers stabilise Zantac, originally marketed by a forerunner of GSK, has been sold by several companies since the loss of patent exclusivity… 3 years ago
Shares of GSK, Sanofi and Haleon decline amid Zantac litigation concerns The drug was marketed by GSK between 1995 and 1998, by Pfizer from 2000 to 2006, by Johnson & Johnson… 3 years ago
Sanofi makes key treatments available on non-profit basis in lower-income countries The countries involved are mainly in Africa, from Niger to Zimbabwe. Conflict-hit countries such as Syria are also part of… 3 years agoJuly 5, 2022
Sanofi slashes price of its insulin product for uninsured US citizen Last year, the Rand Corporation pointed out that the average list price in Canada was $12 compared to $98.70 in… 4 years agoJune 30, 2022
Sanofi to unveil challenge to Medivation’s board Medivation has argued that Sanofi’s offer fails to value fairly the prospects of its recently developed prostate cancer drug XTANDI,… 10 years ago
Sanofi recalls some batches of painkiller Combiflam in India Combiflam is a combination of paracetamol and ibuprofen, and is one of Sanofi’s five biggest brands in India. 10 years ago
Public dengue immunisation program launched in Philippines 1 million students from 6,000 public schools to begin dengue vaccinations this year The first public dengue immunisation programme has… 10 years ago
Merial and Zoetis in strategic agreement Agreement expands Merial portfolio to include 15 new products, making it a key player in the dairy cattle market in… 10 years ago
Sanofi and Innate Pharma collaborate Research collaboration and licensing agreement for new bispecific antibodies will use Innate Pharma’s and Sanofi’s technology to target tumour cells… 10 years ago
Dengvaxia first dengue vaccine approved in Brazil With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue prevention tool… 10 years ago
We are moving into newer disease areas; Xenpozyme will be launched in India soon: Anil Raina, GM, Sanofi Specialty Care, India
